Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
Theravance Biopharma benefits from record sales growth, upcoming Phase 3 CYPRESS data expected Q1 2026 as a key catalyst, positive technical momentum (+27% last month), and strong sector tailwinds, supporting near-term upside despite ongoing losses and high valuation.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Price Behavior
Key Price Behavior Insights: ⢠Lower highs ⢠Tight support ⢠Overhead resistance Support Level: $16.80 Resistance Level: $17.00-$17.60 TBPH has weakened over the last month into a modest downtrend, with lower highs, support near $16.80, and resistance layered from $17.00 to $17.60. ŕ´
Sentiment & News
Key News Insights: ⢠Premium Buyout ⢠Legal Challenges ⢠Cautious Trading Theravance Biopharma agreed to be acquired by Zymeworks for $17.00/share in cash plus a contingent value right, but the deal is facing shareholder scrutiny and a cautious market response.
AI Summary
TBPH should now be viewed as a merger-arbitrage special situation rather than a standalone biotech, with the main investable question being whether investors can capture the $17.00 cash price plus CVR value before closing, while the key downside is spread/headline risk if the deal slips or ampreloxetine monetization disappoints. #M&Aâ
Description
Theravance Biopharma is a biopharmaceutical company that researches, develops and commercializes respiratory medicines across the United States, Europe and Asia, with YUPELRI sold as a nebulized, once-daily therapy for COPD. Its clinical pipeline includes inhaled and gut-targeted small moleculesânotably several JAK inhibitors and other candidates addressing pulmonary and gastrointestinal disordersâalongside later-stage programs for autonomic and motility conditions. The company maintains licensing and collaboration agreements with major pharmaceutical partners and is incorporated in 2013 with headquarters in George Town, Cayman Islands.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Dec 5 | Dec 12 | TBPH | Theravance Biopharma, Inc. | Theravance Biopharma benefits from record sales growth, upcoming Phase 3 CYPRESS data expected Q1 2026 as a key catalyst, positive technical momentum (+27% last month), and strong sector tailwinds, supporting near-term upside despite ongoing losses and high valuation. | Closed | -2.1% |